Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Auteur de référence en rhumatologie
35 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
86 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
23
23 articles ont été cités au moins 23fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
2 505
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
136
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
37
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Université d'Artois
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Development and validation of the FIP-Score for the screening of FIP1L1::PDGFRA-associated hypereosinophilic syndrome
2025ArticleJournal of Allergy and Clinical Immunology: In Practice
Pure Red Cell Aplasia Associated With Thymic Tumors, a Nationwide Retrospective Study
2025ArticleAmerican Journal of Hematology
Mycoplasma pneumoniae infection in adult inpatients during the 2023–24 outbreak in France (MYCADO): a national, retrospective, observational study
2025ArticleThe Lancet Infectious Diseases
Hypereosinophilia and Hypereosinophilic Syndromes: First Findings From a Nationwide Multicenter Cohort
2025ArticleAllergy
The CARMEN-France registry of adult patients with immune thrombocytopenia and autoimmune hemolytic anemia in France
2024ArticleLa Revue de Médecine Interne
Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study
2023ArticleRMD Open
Immune thrombocytopenia and pregnancy: an exposed/nonexposed cohort study
2023ArticleBlood
Efficacy and safety of anakinra in adults presenting deteriorating respiratory symptoms from COVID-19: a randomized controlled trial
2022ArticlePLoS ONE
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
CH BLOIS SIMONE VEIL
MAIL PIERRE CHARLOT, 41016 BLOIS CEDEX
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
European journal of cancer (Oxford, England : 1990) · 2017
Autoimmunity reviews · 2017
American journal of hematology · 2018
AbstractThe aim of the study was to assess the efficacy and safety of rituximab (RTX) for treating systemic lupus erythematosus (SLE)‐associated immune cytopenias. This multicenter retrospective cohort study of adults from French referral centers and networks for adult immune cytopenias and SLE involved patients ≥18 years old with a definite diagnosis of SLE treated with RTX specifically for SLE‐associated immune cytopenia from 2005 to 2015. Response assessment was based on standard definitions. In total, 71 patients, 61 women (85.9%), with median age 36 years [interquartile range 31‐48], were included. The median duration of SLE at the time of the first RTX administration was 6.1 years [2.6‐11.6] and the reason for using RTX was immune thrombocytopenia (ITP) for 44 patients (62.0%), autoimmune hemolytic anemia (AIHA) for 16 (22.5%), Evans syndrome for 10 (14.1%), and pure red cell aplasia for one patient. Before receiving RTX, patients had received a mean of 3.1 ± 1.3 treatments that included corticosteroids (100%), and hydroxychloroquine (88.5%). The overall initial response rate to RTX was 86% (91% with ITP, 87.5% with AIHA, and 60% with Evans syndrome), including 60.5% with complete response. Median follow‐up after the first injection of RTX was 26.4 months [14.3‐71.2]. Among 61 initial responders, relapse occurred in 24 (39.3%); for 18, RTX retreatment was successful in 16 (88.8%). Severe infections occurred after RTX in three patients, with no fatal outcome. No cases of RTX‐induced neutropenia were observed. In conclusion, RTX seems effective and relatively safe for treating SLE‐associated immune cytopenias.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
La Revue de medecine interne · 2025 · English Abstract
Lioger B, Hery L, Comarmond C, Gramont B, et al.
The journal of allergy and clinical immunology. In practice · 2025 · Journal Article
Stammler R, Vallée A, Rohmer J, Grardel N, et al.
Allergy · 2025 · Journal Article
Lefèvre G, Bleuse S, Puyade M, Moulis G, et al.
La Revue de medecine interne · 2024 · Editorial
Nguyen Y, Michon A, Lioger B, Laurent C, et al.
Revue de l'infirmiere · 2023 · English Abstract
Loiret L, Marquet L, Lioger B, Stankovic Stojanovic K
Journal of the American Academy of Dermatology · 2023 · Multicenter Study
Zuelgaray E, Chevret S, Jachiet M, Cacoub P, et al.
Clinical rheumatology · 2022 · Journal Article
Delapierre A, Terrier B, Pillebout E, Baudart P, et al.
Acta dermato-venereologica · 2017 · Case Reports
Thoreau B, Gouaillier-Vulcain F, Machet L, Mateus C, et al.
Annales de dermatologie et de venereologie · 2017 · Case Reports
Chaput L, Rabot N, Limousin N, Cottier JP, et al.
Clinical and experimental rheumatology · 2016 · Journal Article
Lioger B, Diot E, Ebbo M, Schleinitz N, et al.
RMD open · 2023 · Multicenter Study
Mekinian A, Biard L, Lorenzo D, Novikov PI, et al.
Rheumatology (Oxford, England) · 2022 · Journal Article
Mekinian A, Biard L, Dagna L, Novikov P, et al.
RMD open · 2026 · Letter
Mekinian A, Meneses S, Biard L, Dagna L, et al.
Rheumatology (Oxford, England) · 2025 · Journal Article
Mekinian A, Meneses S, Biard L, Dagna L, et al.
RMD open · 2023 · Multicenter Study
Mekinian A, Biard L, Lorenzo D, Novikov PI, et al.
Orphanet journal of rare diseases · 2024 · Journal Article
Moutapam-Ngamby-Adriaansen Y, Maillot F, Labarthe F, Lioger B
The Journal of pediatrics · 2019 · Journal Article
Lioger B, Maillot F, Ternant D, Passot C, et al.
Autoimmunity reviews · 2017 · Journal Article
Durtette C, Hachulla E, Resche-Rigon M, Papo T, et al.
La Revue de medecine interne · 2023 · English Abstract
Perez Y, Belmatoug N, Bengherbia M, Yousfi K, et al.
Blood · 2023 · Observational Study
Guillet S, Loustau V, Boutin E, Zarour A, et al.
European journal of cancer (Oxford, England : 1990) · 2017 · Journal Article
Le Burel S, Champiat S, Mateus C, Marabelle A, et al.
EClinicalMedicine · 2024 · Journal Article
Lobo SM, Plantefève G, Nair G, Joaquim Cavalcante A, et al.
PloS one · 2022 · Journal Article
Audemard-Verger A, Le Gouge A, Pestre V, Courjon J, et al.
Rheumatology (Oxford, England) · 2018 · Journal Article
Guitton Z, Terriou L, Lega JC, Nove-Josserand R, et al.
American journal of hematology · 2018 · Journal Article
Serris A, Amoura Z, Canouï-Poitrine F, Terrier B, et al.
Presse medicale (Paris, France : 1983) · 2020 · Case Reports
Lacasse M, Merlini T, Miquelestorena-Standley E, Maillot F, et al.
Autoimmunity reviews · 2017 · Journal Article
Danlos FX, Rossi GM, Blockmans D, Emmi G, et al.
PloS one · 2022 · Journal Article
Audemard-Verger A, Le Gouge A, Pestre V, Courjon J, et al.
The Journal of pediatrics · 2019 · Journal Article
Lioger B, Maillot F, Ternant D, Passot C, et al.
Rheumatology (Oxford, England) · 2025 · Journal Article
Mekinian A, Meneses S, Biard L, Dagna L, et al.
Clinical rheumatology · 2022 · Journal Article
Hankard A, Ingen-Housz-Oro S, El Karoui K, Paule R, et al.
The Journal of pediatrics · 2019 · Journal Article
Lioger B, Maillot F, Ternant D, Passot C, et al.
The Journal of pediatrics · 2019 · Journal Article
Lioger B, Maillot F, Ternant D, Passot C, et al.
Journal of clinical medicine · 2026 · Journal Article
Morard M, Brebion N, Lambert M, Diot E, et al.
Neurology(R) neuroimmunology & neuroinflammation · 2016 · Journal Article
Lioger B, Ferreira-Maldent N, Cottier JP, Debiais S, et al.
Tocilizumab in treatment-naïve patients with Takayasu arteritis: TOCITAKA French prospective multicenter open-labeled trial
Abstract Objectives To assess long-term efficacy of tocilizumab in treatment-naive patients with Takayasu arteritis (TAK). Methods Prospective open-labeled trial in naïve patients with TAK who received steroids at the do
Blood cytopenias as manifestations of inherited metabolic diseases: a narrative review
Abstract Inherited Metabolic Diseases (IMD) encompass a diverse group of rare genetic conditions that, despite their individual rarity, collectively affect a substantial proportion, estimated at as much as 1 in 784 live
Tocilizumab in treatment-naïve patients with Takayasu arteritis: TOCITAKA French prospective multicenter open-labeled trial
Abstract Objectives To assess long-term efficacy of tocilizumab in treatment-naive patients with Takayasu arteritis (TAK). Methods Prospective open-labeled trial in naïve patients with TAK who received steroids at the do
Blood cytopenias as manifestations of inherited metabolic diseases: a narrative review
Abstract Inherited Metabolic Diseases (IMD) encompass a diverse group of rare genetic conditions that, despite their individual rarity, collectively affect a substantial proportion, estimated at as much as 1 in 784 live
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).
Arthritis research & therapy · 2020 · Journal Article
Mekinian A, Saadoun D, Vicaut E, Thietart S, et al.
The Journal of rheumatology · 2020 · Journal Article
Desbois AC, Biard L, Sène D, Brocheriou I, et al.
European journal of internal medicine · 2019 · Comparative Study
Bayer G, Agier MS, Lioger B, Lepelley M, et al.
Journal of autoimmunity · 2018 · Journal Article
Mekinian A, Resche-Rigon M, Comarmond C, Soriano A, et al.
American journal of hematology · 2018 · Journal Article
Serris A, Amoura Z, Canouï-Poitrine F, Terrier B, et al.
British journal of clinical pharmacology · 2017 · Journal Article
Lioger B, Edupuganti SR, Mulleman D, Passot C, et al.
Neurology(R) neuroimmunology & neuroinflammation · 2016 · Journal Article
Lioger B, Ferreira-Maldent N, Cottier JP, Debiais S, et al.
Rheumatology (Oxford, England) · 2022 · Journal Article
Mekinian A, Biard L, Dagna L, Novikov P, et al.
Arthritis research & therapy · 2020 · Journal Article
Mekinian A, Saadoun D, Vicaut E, Thietart S, et al.
Journal of autoimmunity · 2018 · Journal Article
Mekinian A, Resche-Rigon M, Comarmond C, Soriano A, et al.
Leukemia research · 2016 · Journal Article
Grignano E, Mekinian A, Braun T, Liozon E, et al.
The Journal of pediatrics · 2019 · Journal Article
Lioger B, Maillot F, Ternant D, Passot C, et al.